Details

Autor(en) / Beteiligte

• Hussein, Yaser R., MD
• Sood, Anil K., MD
• Bandyopadhyay, Sudeshna, MD
• Albashiti, Bassam, MD
• Semaan, Assaad, MD
• Nahleh, Zeina, MD
• Roh, Juwon, MD, PhD
• Han, Hee Dong, PhD
• Lopez-Berestein, Gabriel, MD
• Ali-Fehmi, Rouba, MD

Titel

Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer

Ist Teil von

• Human pathology, 2012-10, Vol.43 (10), p.1638-1644

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2012

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• Summary The polycomb group protein, enhancer of zeste homolog 2, is a transcriptional repressor involved in cell cycle regulation and has been linked to aggressive breast cancer. We examined the clinical and biological significance of enhancer of zeste homolog 2 expression in triple-negative breast cancers. Tissue microarrays were constructed with invasive breast cancer cases and stained with the enhancer of zeste homolog 2, cytokeratin 5/6, epidermal growth factor receptor 1, and p53. The expression of these markers was correlated with clinicopathologic variables and patients' outcome. Furthermore, in vivo enhancer of zeste homolog 2 gene silencing was achieved using small interfering RNA incorporated into chitosan nanoparticles. Of 261 cases of invasive breast cancer, high expression of the enhancer of zeste homolog 2 was detected in 87 (33%) cases, and it was strongly associated with a triple-negative breast cancer phenotype ( P < .001) compared with all other non–triple-negative breast cancers. Furthermore, high enhancer of zeste homolog 2 was significantly associated with high histologic grade ( P = .01), estrogen receptor negativity ( P < .001), progesterone receptor negativity ( P < .001), epidermal growth factor receptor positivity ( P = .04), and high p53 expression ( P < .001). Survival analysis demonstrated that patients with high enhancer of zeste homolog 2 had a poorer overall survival compared with those with low enhancer of zeste homolog 2 ( P = .03), and it retained its significance as an independent prognostic factor ( P = .02). In addition, enhancer of zeste homolog 2 gene silencing resulted in a significant reduction in tumor growth ( P < .01) in the orthotopic MB-231 mouse model of breast carcinoma. Our results show that high enhancer of zeste homolog 2 expression is significantly associated with triple-negative breast cancer and decreased survival. Enhancer of zeste homolog 2 may represent a potential therapeutic target for this aggressive disease, which warrants further investigation.